9 completed, 2 not yet recruiting, 1 recruiting, 1 suspended. 15 Phase 2, 1 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 15 | Completed 9, Not yet recruiting 2, Recruiting 1, Suspended 1, Terminated 1, Withdrawn 1 |
| Phase 1 | 1 | Suspended 1 |
| Phase 3 | 1 | Not yet recruiting 1 |
Follow Dyspareunia: new trials by email Literature Review of Dyspareunia trials Research Report on Dyspareunia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| PRECISION-E2: Teverelix in Women With Endometriosis - Pharmacodynamics, Safety and Precision Medicine Correlates Teverelix DP, Teverelix DP Placebo - Endometriosis Pelvic, Endometriosis Ovaries | Phase 2 | Not yet recruiting | Antev Ltd. | 84 | 2027-02-01 | 2026-11-03 |
| Proof of Concept Study of Vaginal AZU-101 in Vulvovaginal Atrophy in Postmenopausal Women Lasofoxifene Tartrate - Vulvo Vaginal Atrophy (VVA) | Phase 2 | Recruiting | Azure Biotech Inc. | 90 | 2026-07-01 | 2026-10-19 |
| Use of Topical Testosterone and Estrogen vs Estrogen Alone in Vulvodynia: a Randomized Controlled Trial Estradiol 0.01% Vag Cream, testosterone 0.1% and estradiol 0.01% vaginal cream - Vulvodynia, Dyspareunia | Phase 2 / Phase 3 | Not yet recruiting | TriHealth Inc. | 44 | 2025-12-01 | 2025-12-03 |
| Carbon Dioxide Fractional Laser in Treating Participants With Stage 0-III Hormone Receptor-Positive Breast Cancer With Vulvovaginal Atrophy Carbon Dioxide Fractional Laser, Questionnaire Administration - Anatomic Stage 0 Breast Cancer AJCC v8, Anatomic Stage I Breast Cancer AJCC v8 | Phase 2 | Withdrawn | Mayo Clinic | 2018-09-10 | 2023-01-06 | |
| Sexual Penetration Pain in Postmenopausal Women: A Topical Botanical Drug Treatment 5% sinecatechins ointment, Placebo, 10% sinecatechins ointment - Sexual Pain Disorders, Postmenopausal Symptoms | Phase 2 | Terminated | GTO Pharmaceutical, LLC | 32 | 2018-08-30 | 2022-07-27 |
| A Study to Assess the Efficacy and Safety of OBE2109 in Subjects With Endometriosis Placebo, OBE2109 - Endometriosis | Phase 2 | Completed | ObsEva SA | 328 | 2016-07-01 | 2022-07-21 |
| A Safety and Efficacy Study of Estradiol Vaginal Capsule in Postmenopausal Women With Vulvovaginal Atrophy Estradiol Vaginal Capsule (EVC), Placebo - Vulvovaginal Atrophy, Menopause | Phase 2 | Completed | Warner Chilcott | 203 | 2016-02-15 | 2017-08-23 |
| TXV13-01 Estradiol Vaginal Softgel Capsules in Treating Postmenopausal Women With Symptoms of Vulvar and Vaginal Atrophy Estradiol, placebo - Menopause, Vulvovaginal Atrophy | Phase 2 | Completed | TherapeuticsMD | 50 | 2013-07-01 | 2015-12-14 |
| Effect of Omega 3 on Atrophic Vaginitis in Breast Cancer Survivors omega-3 fatty acid, placebo, Questionnaire administration - Ductal Breast Carcinoma in Situ, Breast Cancer, Stage I | Phase 2 | Completed | Ohio State University Comprehensive Cancer Center | 52 | 2010-08-01 | 2018-08-09 |
| Pertubation With Lignocaine in Endometriosis Lignocaine, Ringers Solution - Endometriosis, Dysmenorrhea | Phase 2 | Completed | Isifer AB | 42 | 2007-03-01 | 2011-04-06 |
| Vaginal Testosterone Cream For Atrophic Vaginitis in Women Taking Aromatase Inhibitors for Breast Cancer. Testosterone propionate - Vaginitis, Dyspareunia | Phase 1 / Phase 2 | Suspended | University of Vermont | 30 | 2006-12-01 | 2010-05-13 |
| Study Evaluating the Safety and Efficacy of ERB-041 on Reduction of Symptoms Associated With Endometriosis in Reproductive-Aged Women ERB-041 - Dysmenorrhea, Dyspareunia | Phase 2 | Completed | Wyeth is now a wholly owned subsidiary of Pfizer | 150 | 2006-05-01 | 2007-12-10 |
| A Long-Term Study to Evaluate the Safety of Asoprisnil in the Treatment of Women With Endometriosis From Study M01-398 Asoprisnil - Endometriosis | Phase 2 | Completed | Abbott | 73 | 2002-12-01 | 2008-05-29 |
| A Study to Evaluate the Safety and Effectiveness of Asoprisnil in the Treatment of Women With Endometriosis. Asoprisnil, Placebo - Endometriosis | Phase 2 | Completed | Abbott | 131 | 2002-08-01 | 2008-05-29 |
| A Study to Evaluate the Safety and Effectiveness of Three Asoprisnil Doses in the Treatment of Women With Endometriosis Asoprisnil, Placebo - Endometriosis | Phase 2 | Completed | Abbott | 130 | 2000-05-01 | 2008-05-29 |
Dysmenorrhea (7) · Endometriosis (7) · Pelvic Pain (6) · Infertility (4) · Breast Neoplasms (2) · Vulvodynia (2) · Breast Carcinoma In Situ (1) · Carcinoma, Intraductal, Noninfiltrating (1) · Disease (1) · Sexual Dysfunctions, Psychological (1) · Vaginitis (1) · Vulvar Lichen Sclerosus (1)
Female Urogenital Diseases (15) · Female Urogenital Diseases and Pregnancy Complications (15) · Genital Diseases (15) · Genital Diseases, Female (15) · Genital Diseases, Male (15) · Male Urogenital Diseases (15) · Mental Disorders (15) · Sexual Dysfunction, Physiological (15) · Urogenital Diseases (15) · Sexual Dysfunctions, Psychological (14) · Menstruation Disturbances (7) · Neurologic Manifestations (7) · Pain (7) · Pathologic Processes (7) · Pathological Conditions, Signs and Symptoms (7)
asoprisnil (3) · Estradiol (2) · Testosterone (2) · ERB 041 (1) · Fatty Acids, Omega-3 (1) · Fish Oils (1) · Lidocaine (1) · Petrolatum (1) · Ringer's Solution (1) · Testosterone Propionate (1) · Vaginal Creams, Foams, and Jellies (1) · linzagolix (1) · polyphenon E (1)
Abbott (3) · Antev Ltd. (1) · Azure Biotech Inc. (1) · GTO Pharmaceutical, LLC (1) · Isifer AB (1) · Mayo Clinic (1) · ObsEva SA (1) · Ohio State University Comprehensive Cancer Center (1) · TherapeuticsMD (1) · TriHealth Inc. (1) · University of Vermont (1) · Warner Chilcott (1) · Wyeth is now a wholly owned subsidiary of Pfizer (1)
United States (9) · Australia (1) · Belgium (1) · Canada (1) · Hong Kong (1) · Poland (1) · Russia (1) · South Africa (1) · Sweden (1) · Ukraine (1) · United Kingdom (1)
Greta Edelstam, MD (1) · Hyman Muss, MD (1) · Joanne Lester, PhD, CRNP (1) · Lila Nachtigall, M.D. (1) · Marie Wood, MD (1) · ObsEva SA (1) · Sabrina M Witherby, MD (1) · Saranya Chumsri (1) · Shelli Graham, PhD (1) · Vilma Sniukiene, MD (1)